{"id":"https://openalex.org/W2898213950","doi":"https://doi.org/10.1016/j.jaad.2018.10.037","title":"Phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of plaque psoriasis","display_name":"Phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of plaque psoriasis","publication_year":2018,"publication_date":"2018-10-26","ids":{"openalex":"https://openalex.org/W2898213950","doi":"https://doi.org/10.1016/j.jaad.2018.10.037","mag":"2898213950","pmid":"https://pubmed.ncbi.nlm.nih.gov/30612986"},"language":"en","primary_location":{"id":"doi:10.1016/j.jaad.2018.10.037","doi":"https://doi.org/10.1016/j.jaad.2018.10.037","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.jaad.2018.10.037","pdf_url":null,"source":{"id":"https://openalex.org/S58727509","display_name":"Journal of the American Academy of Dermatology","issn_l":"0190-9622","issn":["0190-9622","1097-6787"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-2","ki-jl-3","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of the American Academy of Dermatology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"Kevin Robbins","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Kevin Robbins","raw_affiliation_strings":["GSK, Collegeville, Pennsylvania. Electronic address: kevin.x.robbins@gsk.com","GSK, Collegeville, Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GSK, Collegeville, Pennsylvania. Electronic address: kevin.x.robbins@gsk.com","institution_ids":["https://openalex.org/I4210114143"]},{"raw_affiliation_string":"GSK, Collegeville, Pennsylvania","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029971595","display_name":"Robert Bissonnette","orcid":"https://orcid.org/0000-0001-5927-6587","observed_orcids":["https://orcid.org/0000-0001-5927-6587"]},"institutions":[{"id":"https://openalex.org/I4210138799","display_name":"Innovaderm (Canada)","ror":"https://ror.org/0486db050","country_code":"CA","type":"company","lineage":["https://openalex.org/I4210138799"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Robert Bissonnette","raw_affiliation_strings":["Innovaderm Research Inc, Montreal, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Innovaderm Research Inc, Montreal, Canada","institution_ids":["https://openalex.org/I4210138799"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065619082","display_name":"Tomoko Maeda\u2010Chubachi","orcid":"https://orcid.org/0000-0002-3614-1505","observed_orcids":["https://orcid.org/0000-0002-3614-1505"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Tomoko Maeda-Chubachi","raw_affiliation_strings":["Novan Inc, Morrisville, Raleigh"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novan Inc, Morrisville, Raleigh","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"Li Ye","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Li Ye","raw_affiliation_strings":["GSK, Collegeville, Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GSK, Collegeville, Pennsylvania","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024482733","display_name":"Johnny Peppers","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I920293368","display_name":"PRA Health Sciences","ror":"https://ror.org/02k5t6c64","country_code":"US","type":"facility","lineage":["https://openalex.org/I920293368"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Johnny Peppers","raw_affiliation_strings":["PRA Health Sciences, Raleigh"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"PRA Health Sciences, Raleigh","institution_ids":["https://openalex.org/I920293368"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056607673","display_name":"Kelly Gallagher","orcid":"https://orcid.org/0000-0002-3291-3512","observed_orcids":["https://orcid.org/0000-0002-3291-3512"]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kelly Gallagher","raw_affiliation_strings":["GSK, Collegeville, Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GSK, Collegeville, Pennsylvania","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5112316211","display_name":"John E. Kraus","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"John E. Kraus","raw_affiliation_strings":["ICON plc, Research Triangle Park, North Carolina"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ICON plc, Research Triangle Park, North Carolina","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210114143"],"apc_list":{"value":4200,"currency":"USD","value_usd":4200},"apc_paid":null,"fwci":3.8396,"has_fulltext":false,"cited_by_count":98,"citation_normalized_percentile":{"value":0.94562147,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":100},"biblio":{"volume":"80","issue":"3","first_page":"714","last_page":"721"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10837","display_name":"Dermatology and Skin Diseases","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10704","display_name":"Advancements in Transdermal Drug Delivery","score":0.0,"subfield":{"id":"https://openalex.org/subfields/3003","display_name":"Pharmaceutical Science"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/tapinarof","display_name":"tapinarof","score":0.9990000128746033},{"id":"https://openalex.org/keywords/plaque-psoriasis","display_name":"plaque psoriasis","score":0.8500000238418579},{"id":"https://openalex.org/keywords/topical-cream-formulation","display_name":"topical cream formulation","score":0.6970000267028809},{"id":"https://openalex.org/keywords/dose-finding","display_name":"dose-finding","score":0.8569999933242798},{"id":"https://openalex.org/keywords/frequency-of-use","display_name":"usage frequency","score":0.8119999766349792},{"id":"https://openalex.org/keywords/physician-s-global-assessment","display_name":"physician global assessment","score":0.9150000214576721},{"id":"https://openalex.org/keywords/psoriasis-area-and-severity-index","display_name":"Psoriasis Area and Severity Index","score":0.9929999709129333},{"id":"https://openalex.org/keywords/treatment-emergent-adverse-events","display_name":"treatment-emergent adverse events","score":0.9169999957084656},{"id":"https://openalex.org/keywords/treatment-efficacy-and-safety","display_name":"treatment efficacy and safety","score":0.5180000066757202}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.962037205696106},{"id":"https://openalex.org/C3020604521","wikidata":"https://www.wikidata.org/wiki/Q179945","display_name":"Plaque psoriasis","level":3,"score":0.8256300687789917},{"id":"https://openalex.org/C2780564577","wikidata":"https://www.wikidata.org/wiki/Q179945","display_name":"Psoriasis","level":2,"score":0.6943637728691101},{"id":"https://openalex.org/C16005928","wikidata":"https://www.wikidata.org/wiki/Q171171","display_name":"Dermatology","level":1,"score":0.6019946336746216},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.4923950433731079},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2477211058139801}],"mesh":[{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001830","descriptor_name":"Body Surface Area","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003879","descriptor_name":"Dermatologic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D003879","descriptor_name":"Dermatologic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011565","descriptor_name":"Psoriasis","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D012118","descriptor_name":"Resorcinols","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D012118","descriptor_name":"Resorcinols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D012720","descriptor_name":"Severity of Illness Index","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013267","descriptor_name":"Stilbenes","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D013267","descriptor_name":"Stilbenes","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D063465","descriptor_name":"Skin Cream","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D063465","descriptor_name":"Skin Cream","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1016/j.jaad.2018.10.037","doi":"https://doi.org/10.1016/j.jaad.2018.10.037","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.jaad.2018.10.037","pdf_url":null,"source":{"id":"https://openalex.org/S58727509","display_name":"Journal of the American Academy of Dermatology","issn_l":"0190-9622","issn":["0190-9622","1097-6787"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-2","ki-jl-3","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of the American Academy of Dermatology","raw_type":"journal-article"},{"id":"pmid:30612986","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/30612986","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of the American Academy of Dermatology","raw_type":"Clinical Trial, Phase II"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Randomized Controlled Trial","id":"https://openalex.org/study-designs/randomized-controlled-trial"},{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[{"id":"https://openalex.org/G6905528071","display_name":null,"funder_award_id":"203120","funder_id":"https://openalex.org/F4320307773","funder_display_name":"GlaxoSmithKline"}],"funders":[{"id":"https://openalex.org/F4320307773","display_name":"GlaxoSmithKline","ror":"https://ror.org/01xsqw823"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":26,"referenced_works":["https://openalex.org/W74634963","https://openalex.org/W1583293707","https://openalex.org/W1925087877","https://openalex.org/W1970580490","https://openalex.org/W1973354423","https://openalex.org/W1979058179","https://openalex.org/W2012077729","https://openalex.org/W2017932566","https://openalex.org/W2021018799","https://openalex.org/W2040177546","https://openalex.org/W2106578604","https://openalex.org/W2107432039","https://openalex.org/W2117159275","https://openalex.org/W2138647255","https://openalex.org/W2146291158","https://openalex.org/W2169208261","https://openalex.org/W2171689947","https://openalex.org/W2191300343","https://openalex.org/W2313512314","https://openalex.org/W2612782028","https://openalex.org/W2613116567","https://openalex.org/W2623658276","https://openalex.org/W2752721387","https://openalex.org/W4237627879","https://openalex.org/W4249483860","https://openalex.org/W6645172339"],"related_works":["https://openalex.org/W3027416070","https://openalex.org/W3210474771","https://openalex.org/W4401640183","https://openalex.org/W4366464043","https://openalex.org/W4387014427","https://openalex.org/W3108229751","https://openalex.org/W7160772235","https://openalex.org/W3195864296","https://openalex.org/W4385365580","https://openalex.org/W4200054824"],"abstract_inverted_index":null,"counts_by_year":[{"year":2026,"cited_by_count":8},{"year":2025,"cited_by_count":9},{"year":2024,"cited_by_count":13},{"year":2023,"cited_by_count":18},{"year":2022,"cited_by_count":12},{"year":2021,"cited_by_count":16},{"year":2020,"cited_by_count":15},{"year":2019,"cited_by_count":5},{"year":2018,"cited_by_count":1}],"updated_date":"2026-11-10T11:39:43.021295","created_date":"2018-11-02T00:00:00"}